Brokerages expect Revance Therapeutics Inc (NASDAQ:RVNC) to announce earnings of ($0.97) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Revance Therapeutics’ earnings. The highest EPS estimate is ($0.93) and the lowest is ($1.00). Revance Therapeutics reported earnings per share of ($1.14) in the same quarter last year, which would suggest a positive year over year growth rate of 14.9%. The company is scheduled to issue its next quarterly earnings results on Wednesday, February 27th.
According to Zacks, analysts expect that Revance Therapeutics will report full year earnings of ($3.81) per share for the current fiscal year, with EPS estimates ranging from ($3.82) to ($3.78). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.88) per share, with EPS estimates ranging from ($4.20) to ($3.56). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.04. Revance Therapeutics had a negative net margin of 4,205.52% and a negative return on equity of 61.45%. The company had revenue of $2.36 million for the quarter, compared to analyst estimates of $0.49 million.
RVNC has been the topic of several research reports. Zacks Investment Research lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. JMP Securities lowered shares of Revance Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, September 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price target on shares of Revance Therapeutics in a research report on Friday, September 14th. BidaskClub lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 15th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Revance Therapeutics in a research report on Monday, September 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Revance Therapeutics has a consensus rating of “Buy” and a consensus price target of $46.50.
NASDAQ RVNC opened at $24.20 on Tuesday. Revance Therapeutics has a 12-month low of $19.62 and a 12-month high of $37.45.
In related news, insider Cyril Allouche sold 2,188 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $23.72, for a total transaction of $51,899.36. Following the completion of the transaction, the insider now owns 6,938 shares of the company’s stock, valued at $164,569.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 18.86% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of RVNC. BlackRock Inc. grew its stake in Revance Therapeutics by 21.6% during the second quarter. BlackRock Inc. now owns 2,931,980 shares of the biopharmaceutical company’s stock valued at $80,482,000 after acquiring an additional 521,536 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Revance Therapeutics by 26.7% during the third quarter. Bank of New York Mellon Corp now owns 2,464,617 shares of the biopharmaceutical company’s stock valued at $61,245,000 after acquiring an additional 519,938 shares in the last quarter. Alliancebernstein L.P. grew its stake in Revance Therapeutics by 26.1% during the third quarter. Alliancebernstein L.P. now owns 1,651,949 shares of the biopharmaceutical company’s stock valued at $41,051,000 after acquiring an additional 341,896 shares in the last quarter. Capital International Investors purchased a new position in Revance Therapeutics during the third quarter valued at approximately $8,076,000. Finally, FMR LLC grew its stake in Revance Therapeutics by 223.5% during the third quarter. FMR LLC now owns 350,030 shares of the biopharmaceutical company’s stock valued at $8,699,000 after acquiring an additional 241,830 shares in the last quarter. 92.86% of the stock is owned by institutional investors.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
See Also: Asset Allocation and Your Retirement
Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.